Leerink keeps USD 101.00 target for Edwards Lifesciences stock

Published on 10/17/2026 at 19:31 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Leerink set a USD 101.00 target on October 15, 2026. Edwards Lifesciences stock last stood at EUR 77.06 on October 16, 2026.

Analyst target and market position

Leerink Partners reiterated a Buy rating and set a USD 101.00 target on October 15, 2026.
Edwards Lifesciences reported USD 1.74 billion in second-quarter revenue for 2026.
Edwards Lifesciences stock last stood at EUR 77.06 at Lang & Schwarz on October 16, 2026 at 11:00 p.m. CEST.
The price-to-earnings ratio was 49.77 and market capitalization was USD 49.9 billion on October 16, 2026.

Flatlay-Arrangement mit Aktienzertifikat, ISIN-Karte US28176E1082, Stethoskop und Herzklappen-Modell — Edwards Lifesciences US28176E1082 Flatlay mit Aktienzertifikat ISIN-Karte Stethoskop und Herzklappen-Prothese auf Marmor, Illustration mit AI erstellt.

Leerink Partners reiterated a Buy rating and set a USD 101.00 price target for Edwards Lifesciences on October 15, 2026, according to Markets Insider. The target was set against a cited USD 86.45 share price, leaving a 16.25 percent difference based on those figures. Edwards Lifesciences stock last stood at EUR 77.06 at Lang & Schwarz on October 16, 2026 at 11:00 p.m. CEST.

Second-quarter revenue sets the scale

Edwards Lifesciences generated USD 1.74 billion in revenue in the second quarter of 2026. Operating profit reached USD 513.2 million, while net income attributable to common shareholders was USD 241.9 million for the same period.

Stock position and valuation

The primary listing is on the NYSE under ticker EW. The USD 86.60 last price on October 16, 2026 sat between the 52-week range of USD 74.43 to USD 96.29. The quoted market capitalization was USD 49.9 billion, and the price-to-earnings ratio was 49.77 on that date.

Edwards Lifesciences is scheduled to announce results for the quarter ended September 30, 2026 after the market closes on November 4, 2026. The company will hold its conference call at 5:00 p.m. ET, as stated in the Edwards Lifesciences release.

Comparison with peers

Edwards Lifesciences (NYSE, USD): P/E 49.77, market capitalization USD 49.9 billion.

Medtronic (NYSE, USD): minus 0.73 percent, P/E 23.34, market capitalization USD 121.2 billion.

Abbott Laboratories (NYSE, USD): plus 0.19 percent, P/E 33.72, market capitalization USD 181.5 billion.

November results are next

For investors, the November 4 reporting date is the next concrete calendar marker. The analyst target and the upcoming report frame the stock's valuation discussion, while the 52-week range provides a dated market boundary.

Edwards Lifesciences last stood at EUR 77.06 at Lang & Schwarz on October 16, 2026 at 11:00 p.m. CEST.

The further course of trading is shown by the continuously updated real-time quote of Edwards Lifesciences stock.